Investors

 

Experience cutting edge cancer treatments with Isoray.

Isoray passionately designs and develops innovative and personalized brachytherapy products that effectively treat many forms of cancer. We believe in pioneering solutions for life beyond your cancer.

 

Investor Resources

Governance

Research Analyst Coverage

Ascendiant Capital Markets
Edward Woo

H.C. Wainwright & Co.
Swayampakula Ramakanth, Ph.D.

Do you have questions?

We’ll put you in touch with someone to answer any of your investor related questions.

Our Management Team

 

Transitioning isotopes for prostate brachytherapy: Dr. Bernard Taylor, Texas Oncology

Transition concerns should not stop you from adding Cesium to your prostate brachytherapy practice. With a thoughtful approach to planning and the right support, you can seamlessly upgrade your prostate brachytherapy to the power of Cesium.

Isoray Announces Second Quarter Fiscal 2019 Financial Results

Record Revenue and Gross Profit Revenue Increased 24% Year-Over-Year   RICHLAND, WASHINGTON - February 12, 2019 -- Isoray, Inc. (NYSE AMERICAN:...

Blu Build Featured on WCIV-TV in Charleston, SC

https://write2market.wistia.com/medias/jt4rxq27n7 WCIV-TV reports on the world’s first use of the Blu Build Cesium-131 brachytherapy delivery...

Blu Build Featured on WTAT-TV in Charleston, SC

https://write2market.wistia.com/medias/703bcb1obj The world’s first use of the Blu Build Cesium-131 brachytherapy delivery system to treat prostate...

Isoray To Announce Second Quarter Fiscal 2019 Financial Results on February 12, 2019

Conference Call is February 12 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – January 30, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical...